Patent application number | Description | Published |
20110136815 | SOLID ORAL FILM DOSAGE FORMS AND METHODS FOR MAKING SAME - Improved pharmaceutical solid oral film dosage forms for the buccal and/or sublingual delivery of pharmaceutical, nutraceutical or cosmetic ingredients are endowed with instant hydration potential and complete dissolution potentially enabling the active ingredient to become immediately available for enhanced buccal and/or sublingual absorption and/or reduced absorption through the gastrointestinal route. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced stability by the use of a combination of crystallization inhibitors, which together can maintain the active ingredient in a desired plurality of particles in an effective size range within a polymeric film matrix. | 06-09-2011 |
20110263606 | SOLID ORAL DOSAGE FORMS COMPRISING TADALAFIL - Improved pharmaceutical solid oral dosage forms for the buccal and/or sublingual delivery of Tadalafil. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced methods of preparation by the use improved solubilization systems which can maintain the Tadalafil in a buccal and/or sublingual oral dosage form or a polymeric film matrix that provides improved bioavailability and/or absorption of Tadalafil. | 10-27-2011 |
20130137698 | SOLID ORAL FILM DOSAGE FORMS AND METHODS FOR MAKING SAME - Improved pharmaceutical solid oral film dosage forms for the buccal and/or sublingual delivery of pharmaceutical, nutraceutical or cosmetic ingredients are endowed with instant hydration potential and complete dissolution potentially enabling the active ingredient to become immediately available for enhanced buccal and/or sublingual absorption and/or reduced absorption through the gastrointestinal route. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced stability by the use of a combination of crystallization inhibitors, which together can maintain the active ingredient in a desired plurality of particles in an effective size range within a polymeric film matrix. | 05-30-2013 |
20150038540 | INSTANTLY WETTABLE ORAL FILM DOSAGE FORM WITHOUT SURFACTANT OR POLYALCOHOL - An instantly wettable and rapidly disintegrating oral film dosage form without a surfactant and without a polyalcohol was achieved by combining at least one water soluble polymer that is not a copolymer of vinylpyrrolidone, at least one active agent, a copolymer of vinylpyrrolidone and titanium dioxide. In certain embodiments, the film comprises hydroxypropyl cellulose or a combination of hydroxypropyl cellulose and a polymer or copolymer of vinylpyrrolidone or a substituted vinylpyrrolidone as the water soluble polymer(s). A plasticizer, and optional additives selected from synthetic sweeteners, natural sweeteners, flavorants, antioxidants, colorants, and opacifiers, can be added to the disclosed film oral dosage forms. | 02-05-2015 |
Patent application number | Description | Published |
20080258710 | Analysis of Liquid Chromatography Eluates - When analysing saccharides by HPAEC, the eluate from the column is typically analysed using a amperometric detector. According to the invention, amperometric detection is coupled with ultraviolet detection, with both methods being applied to the eluate. Thus the invention provides a method for analysing the eluate from a liquid chromatography column, wherein the eluate is analysed by both (a) amperometric detection and (b) ultraviolet detection. The information content derivable from using both sorts of detection advantageously exceeds that derivable from either of the two detection methods alone. | 10-23-2008 |
20080274135 | Measuring Degree of Polymerisation for Meningococcal Capsular Saccharides That Contain Sialic Acid - The degree of polymerisation (DP) is an important parameter for analysis of saccharide antigens, particularly in glycoconjugates. The invention provides methods that can be used to measure DP for capsular saccharides, particularly for meningococcal saccharides e.g. from serogroups W135 and Y. A preferred method is based on reduction of terminal sialic acid residues on saccharides, with DP then being calculated by comparing the molar ratio of total sialic acid to reduced sialic acid. | 11-06-2008 |
20080286300 | Analysis of Saccharide Vaccines Without Interference - The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers). The method can be used to analyse total and free saccharide in conjugate vaccines and simplifies quality control of vaccines containing capsular saccharides from multiple serogroups. | 11-20-2008 |
20080305126 | Separation of Unconjugated and Conjugated Saccharide by Solid Phase Extraction - The invention is based on the use of solid phase extraction for separating conjugated saccharide from unconjugated saccharide in sample, e.g. a vaccine. Solid phase extraction (SPE) provides faster and more reproducible separation of conjugated saccharides from unconjugated saccharides, thereby allowing quantitative separation of these saccharides. The separation of conjugated and unconjugated saccharide using SPE may be advantageously combined with a quantitative conjugate analysis to provide improved quality control for conjugate vaccines. The SPE separation is compatible with existing quantitative conjugate analysis techniques, such as high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD). | 12-11-2008 |
20100219335 | Liquid Chromatography-Mass Spectrometry Analysis of Samples Using Ionic Eluent Comprising a Volatile Ionic Salt - The use of an ionic eluent in ion exchange chromatography for analysing a sample comprising an analyte, wherein the ionic eluent comprises a volatile ionic salt, in particular an ammonium salt, is described. Such eluents are shown to be compatible with mass spectrometry (MS), providing clean mass spectra of the analyte. Furthermore, eluates from ion exchange chromatography may be advantageously analysed with MS without additional on-line or off-line devices for desalting or suppressing salts in the eluent. Important information concerning the chemical structure and composition of a sample may therefore be obtained with ion chromatography-MS by utilising the invention. The invention also provides a method of analysing a sample (e.g. a vaccine) comprising an analyte (e.g. a saccharide) by ion chromotography-MS by employing an ionic eluent, wherein the ionic eluent comprises a volatile ionic salt. An apparatus for analysing a sample comprising an analyte is also disclosed. | 09-02-2010 |
20100322958 | MODIFIED SACCHARIDES - Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R | 12-23-2010 |
20110159029 | MEASURING DEGREE OF POLYMERISATION FOR MENINGOCOCCAL CAPSULAR SACCHARIDES THAT CONTAIN SIALIC ACID - The degree of polymerisation (DP) is an important parameter for analysis of saccharide antigens, particularly in glycoconjugates. The invention provides methods that can be used to measure DP for capsular saccharides, particularly for meningococcal saccharides e.g. from serogroups W135 and Y. A preferred method is based on reduction of terminal sialic acid residues on saccharides, with DP then being calculated by comparing the molar ratio of total sialic acid to reduced sialic acid. | 06-30-2011 |
20120171241 | ANALYSIS OF SACCHARIDE VACCINES WITHOUT INTERFERENCE - The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers). The method can be used to analyse total and free saccharide in conjugate vaccines and simplifies quality control of vaccines containing capsular saccharides from multiple serogroups. | 07-05-2012 |
Patent application number | Description | Published |
20100298267 | AMINOPYRIMIDINAMIDES AS PESTICIDES - The present application relates to novel aminopyrimidinamides, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects. | 11-25-2010 |
20110021539 | Pyrazinylpyrazoles - Pyrazin-2-ylpyrazoles are described, as is the use thereof as insecticides and/or parasiticides. | 01-27-2011 |
20110071141 | Pesticidial Condensed-Ring Aryl Compounds - Condensed-ring aryl compounds of formula (I) and use of the same as a agrochemical for controlling noxious organisms wherein (X) | 03-24-2011 |
20110105472 | Diaminopyrimidines as crop protection agents - Use of diaminopyrimidines of the formula (I) | 05-05-2011 |
20110105532 | Haloalkyl-substituted amides as insecticides and acaricides - The present invention relates to halogen-substituted amide derivatives of the general formula (I) | 05-05-2011 |
20110152322 | Aminopropenoates as Fungicides - The present invention relates to aminopropenoate derivatives, the process of their preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants and in material protection, using these compounds or compositions. | 06-23-2011 |
20110190365 | Insecticidal 4-phenyl-1H-pyrazoles - The present invention relates to novel 4-phenyl-1H-pyrazoles and their use as insecticides and/or parasiticides and also to processes for their preparation and to compositions comprising such phenylpyrazoles. | 08-04-2011 |
20110212949 | Heterocyclic Compounds as Pesticides - The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests, including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation. | 09-01-2011 |
20110301181 | halogen-substituted compounds - The invention relates to compounds of the general formula (I), | 12-08-2011 |
20110306645 | Novel ortho-substituted arylamide derivatives - The present invention relates to novel ortho-substituted arylamide derivatives of the general formula (I) | 12-15-2011 |
20120065164 | FUNGICIDE PYRAZOLE CARBOXAMIDES DERIVATES - The present invention relates to pyrazole carboxamides derivatives of formula (1) wherein Y represents CR | 03-15-2012 |
20120071496 | Aminopyrimidinamides As Pest Control Agents - The present application relates to novel aminopyrimidinamides, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects. | 03-22-2012 |
20120094837 | Novel Heterocyclic Compounds as Pesticides - The present invention relates to novel heterocyclic compounds, to processes for preparation thereof and to the use thereof for controlling animal pests, which include arthropods and especially insects. | 04-19-2012 |
20120190687 | Pyrazinylpyrazoles - Pyrazin-2-ylpyrazoles are described, as is the use thereof as insecticides and/or parasiticides. | 07-26-2012 |
20130172390 | Haloalkyl-Substituted Amides as Insecticides and Acaricides - The present invention relates to halogen-substituted amide derivatives of the general formula (I) | 07-04-2013 |
20130305417 | Double-Stranded RNA Constructs to Control Insect Pests - Disclosed is a dsRNA construct that relates to a method to control insect pests of the genus | 11-14-2013 |
20140018377 | Aminopropenoates as Fungicides - This application claims priority to European Patent Application No. 09173304.8, filed Oct. 16, 2009, and the benefit of U.S. Provisional Application No. 61/253,091, filed Oct. 20, 2009, the disclosure of each of which is incorporated by reference herein in its entirety. | 01-16-2014 |
20140088167 | INDOLECARBOXAMIDES AND BENZIMIDAZOLECARBOXAMIDES AS INSECTICIDES AND ACARICIDES - The present invention relates to compounds of the general formula (I) | 03-27-2014 |
20140148411 | FUNGICIDE PYRAZOLE CARBOXAMIDES DERIVATIVES - The present invention relates to pyrazole carboxamides derivatives of formula (1) wherein Y represents CR | 05-29-2014 |
20140336186 | Heterocyclic Compounds as Pesticides - The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests, including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation. | 11-13-2014 |
Patent application number | Description | Published |
20110139677 | CATALYTIC SYSTEM AND PROCESS FOR THE HYDROCONVERSION OF HEAVY OIL PRODUCTS - Catalytic system which can be used in processes for the hydroconversion of heavy oils by means of hydrotreatment in slurry phase, characterized in that it comprises: a catalyst, having the function of hydrogenating agent, containing MoS | 06-16-2011 |
20120059181 | HYBRID, ORGANIC-INORGANIC, CRYSTALLINE, POROUS SILICATES AND METAL-SILICATES - The present invention relates to new hybrid, organic-inorganic hybrid silicates and metal-silicates characterized by a crystalline structure containing structural units having formula (a), wherein R is an organic group possibly containing one or more element T selected from Group IIIB, IVB, VB and from transition metals. A process starting from cyclic trisilanes for the preparation of said materials, is also described. These materials can be used as molecular sieves, adsorbents, in the field of catalysis, in the field of electronics, in the field of sensors, in the area of nanotechnology. | 03-08-2012 |
Patent application number | Description | Published |
20090288557 | PROCESS AND ZEOLITIC MATERIALS FOR THE SEPARATION OF GASES - The present invention relates to a process for the separation of gases which comprises putting a mixture of gases in contact with a zeolite of the ESV type to obtain the selective adsorption of at least one of the gases forming the gaseous mixture. The present invention also relates to particular zeolitic compositions suitable as adsorbents. | 11-26-2009 |
20100191009 | ORGANIC-INORGANIC HYBRID SILICATES AND METAL-SILICATES HAVING AN ORDERED STRUCTURE - The present invention relates to new organic-inorganic hybrid silicates and metal-silicates called ECS, characterized by an X-ray powder diffraction pattern with reflections exclusively at angular values higher than 4.0° of 2Θ, preferably at angular values higher than 4.7°, and an ordered structure containing structural units having formula (a) wherein R is an organic group: Formula (a) and possibly containing one or more elements T selected from groups III B, IV B, V B and transition metals, with a Si/(Si+T) molar ratio in said structure higher than 0.3 and lower than or equal to 1, wherein Si is the silicon contained in the structural unit (a). A process is also described, starting from disilanes, for the preparation of these materials, which does not include the use of templates or surfactants. These materials can be used as molecular sieves, adsorbents, in the field of catalysis, in the field of electronics, in the field of sensors, in the field of nanotechnologies. | 07-29-2010 |
20100331576 | PROCESS FOR THE PREPARATION OF TS-1 ZEOLITES - The invention relates to a new process which allows the preparation of TS-1 zeolites in a pure phase and with a crystallinity higher than 95%, operating at reduced reaction volumes, and obtaining high productivities and extremely high crystallization yields. The particular crystalline form of the TS-1 zeolite thus prepared, is also described. | 12-30-2010 |
20140154174 | PROCESS AND ZEOLITIC MATERIALS FOR THE SEPARATION OF GASES - The present invention relates to a process for the separation of gases which comprises putting a mixture of gases in contact with a zeolite of the ESV type to obtain the selective adsorption of at least one of the gases forming the gaseous mixture. The present invention also relates to particular zeolitic compositions suitable as adsorbents. | 06-05-2014 |
Patent application number | Description | Published |
20080241564 | CIRCUIT ARCHITECTURE ON AN ORGANIC BASE AND RELATED MANUFACTURING METHOD - A method comprises providing a bottom electrode, depositing, on the bottom electrode, an active material comprising a first structural portion having an absorption peak at a UV wavelength, wherein such first structural portion is photo-activatable at such wavelength and which is constituted by monomers or oligomers that, when irradiated at said wavelength, undergo a photo-polymerization and/or photo-cross-linking reaction, or constituted by a polymer that at a UV wavelength undergoes a photo-degradation reaction, and a second electrically active or activatable structural portion which is substantially transparent to such predetermined UV wavelength; exposing a portion of the active material, through a photomask, to UV radiation having such UV wavelength, with photo-activation of the exposed portion of such film; selectively removing either the exposed photo-activated portion or the non-exposed portion, with exposure of a respective portion of the bottom electrode; depositing a head electrode. | 10-02-2008 |
20110275018 | CIRCUIT ARCHITECTURE ON AN ORGANIC BASE AND RELATED MANUFACTURING METHOD - A method comprises providing a bottom electrode, depositing, on the bottom electrode, an active material comprising a first structural portion having an absorption peak at a UV wavelength, wherein such first structural portion is photo-activatable at such wavelength and which is constituted by monomers or oligomers that, when irradiated at said wavelength, undergo a photo-polymerization and/or photo-cross-linking reaction, or constituted by a polymer that at a UV wavelength undergoes a photo-degradation reaction, and a second electrically active or activatable structural portion which is substantially transparent to such predetermined UV wavelength; exposing a portion of the active material, through a photomask, to UV radiation having such UV wavelength, with photo-activation of the exposed portion of such film; selectively removing either the exposed photo-activated portion or the non-exposed portion, with exposure of a respective portion of the bottom electrode; depositing a head electrode. | 11-10-2011 |
Patent application number | Description | Published |
20090175937 | Misuse Preventative, Controlled Release Formulation - Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 07-09-2009 |
20110015205 | Trazodone Composition for Once a Day Administration - The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders. | 01-20-2011 |
20110021535 | Trazodone Composition for Once a Day Administration - The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders. | 01-27-2011 |
20130344142 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 12-26-2013 |
20140193494 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the coreswells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 07-10-2014 |
20140294954 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a first layer and a second layer. The core comprises a superabsorbent material (for example, polycarbophil), and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to create a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 10-02-2014 |
Patent application number | Description | Published |
20100029897 | ANION-BINDING POLYMERS AND USES THEREOF - Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described. | 02-04-2010 |
20130022570 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS - The present invention provides a crosslinked amine and amide polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritis, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like. | 01-24-2013 |
20130189215 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS - The present invention provides crosslinked amine polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritus, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like. | 07-25-2013 |
20140356316 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS - The present invention provides crosslinked amine polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritus, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like. | 12-04-2014 |
Patent application number | Description | Published |
20110225939 | CLEAN SCREEN AIR FILTRATION SYSTEM - A clean screen air filtration system for increasing the filtration of allergens, dust particles, and airborne pollutants from air exiting an air duct. In a preferred embodiment, a user may removably attach a clean screen air filtration system assembly to an existing air duct via a magnetic fastening strip affixed along a backside of an air filter frame. The magnetic fastening strip may provide an efficient means for removably attaching the clean screen air filtration system assembly to the outside of an existing air duct manufactured from a metallic material. The clean screen air filtration system assembly may comprise at least one replaceable air filter. The air filter may comprise a ventilation screen having a plurality of miniature, slatted filter apertures, a flexible air filter frame, and an air filter handle/tab. The user may slidably insert air filter via the filter handle/tab into a filter track located inside a gap region integrated within the air filter frame. The gap region may comprise a width and depth just large enough to receive the air filter such that only the filter handle/tab extends beyond the air filter frame for ease of replacement. | 09-22-2011 |
20120028227 | myWriteRightpen - A digital pen designed to assist users in spelling words as they write. The invention is an electronic pen with a speaker located near the top of the device. A microphone may be located directly under the speaker in the form of a small screened concave or convex aperture. A switch on the back of the pen allows the user to choose between three settings: Dictionary (D), Off (O), and Thesaurus (T). The device works by the user speaking the desired word into the microphone. The word will then appear on the illuminated digital display screen which lights up. The pen asks the user to confirm or deny the displayed word. The user says “yes” or “no” into the microphone. If denied, the pen displays another word until the correct word is located. Once confirmed, the pen will audibly and visibly spell the word one letter at a time as the user writes. The pen may be switched to the thesaurus mode when synonyms/antonyms are needed. | 02-02-2012 |
20120028228 | myLegalpen - A digital pen designed to assist users in spelling words as they write. The invention is an electronic pen with a speaker located near the top of the device. A microphone may be located directly under the speaker in the form of a small screened concave or convex aperture. A switch on the back of the pen allows the user to choose between three settings: Legal Dictionary (D), Off (0), and Legal Thesaurus (T). The device works by the user speaking the desired word into the microphone. The word will then appear on the illuminated digital display screen which lights up. The pen asks the user to confirm or deny the displayed word. The user says “yes” or “no” into the microphone. If denied, the pen displays another word until the correct word is located. Once confirmed, the pen will audibly and visibly spell the word one letter at a time as the user writes. The pen may be switched to the legal thesaurus mode when synonyms/antonyms are needed. | 02-02-2012 |
20120029907 | myMedicalpen - A digital pen designed to assist users in spelling words as they write. The invention is an electronic pen with a speaker located near the top of the device. A microphone may be located directly under the speaker in the form of a small screened concave or convex aperture. A switch on the back of the pen allows the user to choose between three settings: Medical Dictionary (D), Off (O), and Prescription Drug List (P). The device works by the user speaking the desired word into the microphone. The word will then appear on the illuminated digital display screen which lights up. The pen asks the user to confirm or deny the displayed word. The user says “yes” or “no” into the microphone. If denied, the pen displays another word until the correct word is located. Once confirmed, the pen will audibly and visibly spell the word one letter at a time as the user writes. The pen may be switched to the prescription drug list mode as needed. | 02-02-2012 |
Patent application number | Description | Published |
20110129562 | Nanosized Carotenoid Cyclodextrin Complexes - Methods for the preparation of nanosized nutrient formulations for enhanced absorption of nutritional agents. The methods include the complexation of cyclodextrin with carotenoids and incorporation of the complexes into the nutritional supplements without intermediate collection, isolation, and drying steps. | 06-02-2011 |
20120134976 | ORAL FORMULATIONS FOR COUNTERACTING EFFECTS OF AGING - An oral formulation as described herein can comprise pomegranate extract, panax ginseng extract, and | 05-31-2012 |
20130071369 | Oral Formulations For Promoting Cellular Purification - An oral formulation includes a plurality of agents that promote cellular detoxification. Agents can be included that modulate expression of Nrf2-associated genes upon ingestion of the oral formulation by a subject, wherein the Nrf2-associated genes include at least one gene encoding intrinsic antioxidants, and at least one gene encoding cellular detoxifiers. In addition, at least one of the plurality of agents attenuates inflammation. | 03-21-2013 |
20130178379 | Identifying Markers of Caloric Restriction and Caloric Restriction Mimetics - Markers of caloric restriction (CR) can be identified in a selected tissue by exposing an animal to CR conditions and selecting one or more genes differentially expressed in response to CR conditions in multiple subject groups. A candidate compound can be screened for likely ability to mimic the effects of CR when administered to an animal by comparing the tissue levels of expression products of the genes in animals treated with the candidate compound to those of animals subjected to CR. | 07-11-2013 |
Patent application number | Description | Published |
20090258010 | METHODS, COMPOSITIONS, AND KITS FOR TREATING SHIGA TOXIN ASSOCIATED CONDITIONS - The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (cαStx1) and anti-Shiga Toxin 2 (cαStx2) antibodies. | 10-15-2009 |
20100166753 | HUMANIZED MONOCLONAL ANTIBODIES THAT PROTECT AGAINST SHIGA TOXIN INDUCED DISEASE - The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention. | 07-01-2010 |
20100189715 | HUMANIZED MONOCLONAL ANTIBODIES THAT PROTECT AGAINST SHIGA TOXIN INDUCED DISEASE - The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention. | 07-29-2010 |
20110318357 | METHODS AND COMPOSITIONS BASED ON SHIGA TOXIN TYPE 2 PROTEIN - The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with | 12-29-2011 |
20120195891 | METHODS, COMPOSITIONS, AND KITS FOR TREATING SHIGA TOXIN ASSOCIATED CONDITIONS - The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (cαStx1) and anti-Shiga Toxin 2 (cαStx2) antibodies. | 08-02-2012 |
20130101591 | METHODS AND COMPOSITIONS BASED ON SHIGA TOXIN TYPE 1 PROTEIN - The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of the Stx1 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with | 04-25-2013 |
20140023652 | METHODS AND COMPOSITIONS BASED ON SHIGA TOXIN TYPE 1 PROTEIN - The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of the Stx1 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with | 01-23-2014 |
20140135481 | HUMANIZED MONOCLONAL ANTIBODIES THAT PROTECT AGAINST SHIGA TOXIN INDUCED DISEASE - The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention. | 05-15-2014 |
Patent application number | Description | Published |
20110035600 | METHOD AND DEVICE FOR TRANSCODING DURING AN ENCRYPTION-BASED ACCESS CHECK ON A DATABASE - A device for transcoding during an encryption-based access check of a client device to a databank, which provides a data set in an encrypted area, has: a unit for assigning a specific access level of the client device and for providing a corresponding first group key of the client device as a function of a registration parameter, wherein the client device is allowed access to a first area, which is encrypted using the first group key, and all areas of the database subordinate to the first area as a function of the assigned access level; a unit for providing a classification result depending on a classification of the data set of the particular area by one of the client devices allowed to access the particular area; and a unit for transcoding the data set and/or a data set key for the data set as a function of the classification result. | 02-10-2011 |
20120124385 | METHOD, CONTROLLER AND SYSTEM FOR DETECTING INFRINGEMENTS OF THE AUTHENTICITY OF SYSTEM COMPONENTS - In a method for detecting infringements of the authenticity of a system component an authentication request is sent from a controller to an authentication device of the system component. A first authentication code is calculated in the authentication device by applying a shared one-way function to an identification code, stored in the authentication device, for the system component. A second authentication code in the controller is calculated by applying the shared one-way function to an identification code, stored in the controller, for the system component, and an authentication response including the first authentication code is sent from the authentication device to the controller. The first authentication code is compared with the second authentication code in the controller for detecting infringements of the authenticity of the system component. | 05-17-2012 |
20120154111 | METHOD FOR INSPECTING A PRODUCT AS AN ORIGINAL PRODUCT OF A PRODUCT PRODUCER - Against the background of continually growing problems of product piracy, in particular due to the further expansion and liberalization of international trade, there is great demand for automated and reliable inspection of the authenticity of products. The present disclosure relates to methods and systems for inspecting a product as an original product of a product producer by authenticating at least one RFID (Radio Frequency Identification) tag allocated to the product using an asymmetrical challenge response protocol. | 06-21-2012 |
20140006574 | Network Device and Method for Operating a Network Device for an Automation Network | 01-02-2014 |
20140173688 | Method and System for Providing Device-Specific Operator Data for an Automation Device in an Automation Installation - Method and system for providing device-specific operator data for an automation device in an automation installation, which automation device authenticates itself to an authentication server in the automation installation via at least one authentication credential, wherein if up-to-date device-specific operator data from the installation operator of the automation installation are available for the automation device, then the up-to-date device-specific operator data are tied to the authentication credential of the authentication device. | 06-19-2014 |
20140328483 | METHOD FOR PRODUCING A HARDWARE DEVICE AND HARDWARE DEVICE - A method for producing a hardware device, in particular a trusted platform module for the execution of at least one cryptographic algorithm, the hardware device corresponding to a real-time class, i.e., it fulfils specifiable run-time requirements for real-time applications, wherein the method comprises preparing at least one cryptographic algorithm in the manner of a program code; determining a maximum/longest execution time (WCET) for the algorithm, producing a tamper-proof hardware module, which is configured to execute the algorithm, and assigning the hardware module to a real-time class depending on the maximum/longest execution time (WCET). | 11-06-2014 |
20140358257 | System and method for providing a control program code - A system for providing a control program code (SPC) for controlling a device connected to a control device has: an authentication service which, after successful authentication of the device with respect to the authentication service, transmits a device ID (FG-ID) of the authenticated device to a commissioning service which, on the basis of the device ID (FG-ID) of the authenticated device, transmits a control program code (SPC) to a control device which controls the authenticated device using the control program code (SPC). | 12-04-2014 |
20150052060 | Plagiarism Protection - The embodiments relate to methods for plagiarism protection for cryptographic challenge-response methods, wherein an originality test for products that require a secret symmetric or private asymmetric key on the product side is carried out such that a plagiarism protection service is set up as a web service that carries out a calculation of the challenge for the product to be tested and a verification of the response for the product and sends the result of the verification in an integrity-protected manner to a testing unit authorized for plagiarism testing, and which, if the cryptographic challenge-response method is not present on the product to be tested after the key has been authenticated and authorized by the product to be tested, can subsequently send software for calculating the response directly to the product online. | 02-19-2015 |
Patent application number | Description | Published |
20100121360 | Testing a patient population having a cardiovascular condition for drug efficacy - Lumenectomy material is tested to determine the efficacy of a test drug in a patient population having a cardiovascular condition. The material is removed from at least a first and a second patient and tested for one or more markers of a cardiovascular condition. The first patient is administered the test drug, and the second patient is administered a placebo. At a later date, more lumenectomy material is removed and tested for the same marker or markers. The presence, absence or amount of the markers is compared in the first patient receiving the drug and the second patient receiving the placebo to determine whether the drug is effective in the patient population. The patient population can comprise as little as two individuals or as many as dozens, hundreds or thousands of patients. The drugs tested include drugs believed to be effective in treating a cardiovascular condition. The markers used can include any marker that can indicate the effectiveness of the drug being tested, including amino acid and nucleic acid markers and markers that indicate a cardiovascular condition. | 05-13-2010 |
20110060606 | LIBRARIES AND DATA STRUCTURES OF MATERIALS REMOVED BY DEBULKING CATHETERS - Material removed by a debulking catheter from a body lumen can be preserved. Materials can be collected from many different patients and/or from multiple procedures on individual patients. Data which describe the properties or qualities of the removed material and/or the patient and/or the patient's family or environment can be stored on computer readable media. The stored data can be used to draw correlations, to stratify groups of patients, to provide risk assessments, to provide diagnoses and/or prognoses. Further tests can be done on the stored materials at later times after the procedures have been completed. | 03-10-2011 |
20110236902 | TESTING A PATIENT POPULATION HAVING A CARDIOVASCULAR CONDITION FOR DRUG EFFICACY - Lumenectomy material is tested to determine the efficacy of a test drug in a patient population having a cardiovascular condition. The material is removed from at least a first and a second patient and tested for one or more markers of a cardiovascular condition. The first patient is administered the test drug, and the second patient is administered a placebo. At a later date, more lumenectomy material is removed and tested for the same marker or markers. The presence, absence or amount of the markers is compared in the first patient receiving the drug and the second patient receiving the placebo to determine whether the drug is effective in the patient population. The drugs tested include drugs believed to be effective in treating a cardiovascular condition. The markers used can include any marker that can indicate the effectiveness of the drug being tested. | 09-29-2011 |
20110250593 | TESTING LUMENECTOMY SAMPLES FOR MARKERS OF NON-VASCULAR DISEASES - Lumenectomy material is tested to determine the presence or likelihood of a condition of a patient. The lumenectomy material is in the form of at least one continuous tissue strand collected in vivo from an inner surface of a body lumen of the patient. The presence of at least one marker of a disease is determined. The disease may be hypertension, hyperlipidemia, depression, obesity, metabolic syndrome, insulin resistance, kidney damage, or diabetes. The patient is identified as having or as likely to develop the disease if a marker of the disease is identified in the lumenectomy material of the patient. | 10-13-2011 |
20120129163 | TESTING LUMENECTOMY SAMPLES FOR MARKERS OF NON-VASCULAR DISEASES - Lumenectomy material is tested to determine the presence or likelihood of a condition of a patient. The lumenectomy material is in the form of at least one continuous tissue strand collected in vivo from an inner surface of a body lumen of the patient. The presence of at least one marker of a disease is determined. The disease may be hypertension, hyperlipidemia, depression, obesity, metabolic syndrome, insulin resistance, kidney damage, or diabetes. The patient is identified as having or as likely to develop the disease if a marker of the disease is identified in the lumenectomy material of the patient. | 05-24-2012 |
20120322688 | TESTING LUMENECTOMY SAMPLES FOR MARKERS OF NON-VASCULAR DISEASES - Lumenectomy material is tested to determine the presence or likelihood of a condition of a patient. The lumenectomy material is in the form of at least one continuous tissue strand collected in vivo from an inner surface of a body lumen of the patient. The presence of at least one marker of a disease is determined. The disease may be hypertension, hyperlipidemia, depression, obesity, metabolic syndrome, insulin resistance, kidney damage, or diabetes. The patient is identified as having or as likely to develop the disease if a marker of the disease is identified in the lumenectomy material of the patient. | 12-20-2012 |
20130012411 | TESTING A PATIENT POPULATION HAVING A CARDIOVASCULAR CONDITION FOR DRUG EFFICACY - Lumenectomy material is tested to determine the efficacy of a test drug in a patient population having a cardiovascular condition. The material is removed from at least a first and a second patient and tested for one or more markers of a cardiovascular condition. The first patient is administered the test drug, and the second patient is administered a placebo. At a later date, more lumenectomy material is removed and tested for the same marker or markers. The presence, absence or amount of the markers is compared in the first patient receiving the drug and the second patient receiving the placebo to determine whether the drug is effective in the patient population. The drugs tested include drugs believed to be effective in treating a cardiovascular condition. The markers used can include any marker that can indicate the effectiveness of the drug being tested. | 01-10-2013 |
20130013216 | LIBRARIES AND DATA STRUCTURES OF MATERIALS REMOVED BY DEBULKING CATHETERS - Material removed by a debulking catheter from a body lumen can be preserved. Materials can be collected from many different patients and/or from multiple procedures on individual patients. Data which describe the properties or qualities of the removed material and/or the patient and/or the patient's family or environment can be stored on computer readable media. The stored data can be used to draw correlations, to stratify groups of patients, to provide risk assessments, to provide diagnoses and/or prognoses. Further tests can be done on the stored materials at later times after the procedures have been completed. | 01-10-2013 |
Patent application number | Description | Published |
20090176998 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alka-noates thereof - The present invention relates to novel processes for the manufacture of chroman derivatives such as α-tocopherol (TCP) and alkanoates thereof, especially α-tocopheryl acetate (TCPA), whereby at least one step of the processes is carried out in the presence of a Lewis acid or a mixture of a Lewis acid with a Bronsted acid as the catalyst under pressure, preferably at an absolute pressure of at least 1.1 bar. | 07-09-2009 |
20090221860 | TRANSPORT OF ETHYNE IN FORM OF A-ALKYNOLS AS ETHYNE PRECURSORS - The present invention relates to a new method for a safe transport of ethyne in form of α-alkynols as precursors for ethyne. The new method comprises three steps. In a first step the synthesis of the α-alkynol(s) is performed by reacting ethyne with (a) carbonyl compound(s). The second step comprises the transport of the resulting α-alkynol(s) in a safe manner, whereas the safety requirements for this transport are not as high as for ethyne because α-alkynol(s) are normally classified for transportation as hazardous class 3. In the third step the α-alkynol(s) can be cleaved and the ethyne and the carbonyl compound(s) can be obtained in the cleavage reaction and can be separated to yield pure products for further applications. | 09-03-2009 |
20090287002 | Process for the working-up of a vitamin E- and vitamin E-acetate- containing mixture or products stream - The invention relates to a process for the working-up of a vitamin E (VE)- and/or vitamin E acetate (VEA)-containing product stream, which is substantially characterized by purification of a vitamin E-containing product stream, acetylation of at least a part of the purified vitamin E and purification of at least a part of the acetylated vitamin E, the purification of vitamin E and vitamin E acetate preferably being effected by distillation, for example rectification. A preferred process according to the invention is characterized in that a vitamin E-containing product stream is fed to a first rectification column ( | 11-19-2009 |
20110036702 | PROCESS FOR THE RECTIFICATION OF MIXTURES OF HIGH-BOILING AIR- AND/OR TEMPERATURE-SENSITIVE USEFUL PRODUCTS - According to the invention, a process for the rectification of mixtures of high-boiling air- and/or temperature-sensitive substances which require a high separation efficiency is proposed, in particular a process for the working-up of a VE- or VEA-containing product stream. The process is characterized in particular in that, in a first purification stage, low-boiling products and unspecified isomers of the useful product are separated from the product stream virtually without loss of useful product and that, in a second purification stage, the useful product is removed in a stream having a purity of >97% by weight and a further stream having a purity of >92% by weight. A preferred embodiment of the process serves for working up VEA, in which the loss of useful product in the first purification stage is less than 5%, based on that amount of VEA in the feed which is added to the purification stage per unit time. Furthermore, the first purification stage may comprise a rectification column ( | 02-17-2011 |
20120156107 | PROCESS FOR THE WORKING-UP OF A VITAMIN E- AND VITAMIN E-ACETATE-CONTAINING MIXTURE OR PRODUCT STREAM - A rectification column and system for the working-up of a vitamin E (VE)- and/or vitamin E acetate (VEA)-containing product stream includes purification of a vitamin E-containing product stream, acetylation of at least a part of the purified vitamin E and purification of at least a part of the acetylated vitamin E, the purification of vitamin E and vitamin E acetate preferably being effected by distillation, for example rectification. | 06-21-2012 |
20130284581 | PROCESS FOR THE RECTIFICATION OF MIXTURES OF HIGH-BOILING AIR- AND/OR TEMPERATURE-SENSITIVE USEFUL PRODUCTS - A process for the rectification of mixtures of high-boiling air- and/or temperature-sensitive substances which require a high separation efficiency is proposed, in particular a process for the working-up of a VE- or VEA-containing product stream. The process includes a first purification stage to separate low-boiling products and unspecified isomers of the useful product from the product stream virtually without loss of useful product and a second purification stage for removing the useful product in a stream having a purity of >97% by weight and a further stream having a purity of >92% by weight. | 10-31-2013 |